The 36-month beta value for VINC is at 1.08. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for VINC is 21.59M, and currently, shorts hold a 2.01% of that float. The average trading volume for VINC on June 27, 2024 was 728.70K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
VINC) stock’s latest price update
The stock price of Vincerx Pharma Inc (NASDAQ: VINC) has jumped by 10.95 compared to previous close of 0.59. Despite this, the company has seen a gain of 8.92% in its stock price over the last five trading days. globenewswire.com reported 2024-05-14 that Vincerx continued to progress Phase 1 dose-escalation studies for VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC), and VIP236, a first-in-class small molecule-drug conjugate (SMDC)
VINC’s Market Performance
Vincerx Pharma Inc (VINC) has seen a 8.92% rise in stock performance for the week, with a -0.67% decline in the past month and a -89.20% plunge in the past quarter. The volatility ratio for the week is 5.50%, and the volatility levels for the past 30 days are at 7.87% for VINC. The simple moving average for the past 20 days is -0.56% for VINC’s stock, with a -61.07% simple moving average for the past 200 days.
Analysts’ Opinion of VINC
Many brokerage firms have already submitted their reports for VINC stocks, with H.C. Wainwright repeating the rating for VINC by listing it as a “Buy.” The predicted price for VINC in the upcoming period, according to H.C. Wainwright is $25 based on the research report published on January 14, 2022 of the previous year 2022.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see VINC reach a price target of $25. The rating they have provided for VINC stocks is “Overweight” according to the report published on December 23rd, 2021.
SVB Leerink gave a rating of “Outperform” to VINC, setting the target price at $24 in the report published on November 01st of the previous year.
VINC Trading at -12.77% from the 50-Day Moving Average
After a stumble in the market that brought VINC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.02% of loss for the given period.
Volatility was left at 7.87%, however, over the last 30 days, the volatility rate increased by 5.50%, as shares sank -2.26% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -31.36% lower at present.
During the last 5 trading sessions, VINC rose by +7.32%, which changed the moving average for the period of 200-days by -11.64% in comparison to the 20-day moving average, which settled at $0.6575. In addition, Vincerx Pharma Inc saw -44.53% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VINC starting from Seelenberger Alexander A., who purchase 10,500 shares at the price of $0.95 back on Aug 11 ’23. After this action, Seelenberger Alexander A. now owns 30,280 shares of Vincerx Pharma Inc, valued at $9,968 using the latest closing price.
Hamdy Ahmed MD purchase 5,400 shares at $0.96 during a trade that took place back on Aug 10 ’23, which means that Hamdy Ahmed MD is holding 96,060 shares at $5,167 based on the most recent closing price.
Stock Fundamentals for VINC
Current profitability levels for the company are sitting at:
- -26.63 for the present operating margin
- 0.22 for the gross margin
The net margin for Vincerx Pharma Inc stands at -29.11. The total capital return value is set at -77.92. Equity return is now at value -226.01, with -130.68 for asset returns.
Based on Vincerx Pharma Inc (VINC), the company’s capital structure generated 1.39 points at debt to capital in total, while cash flow to debt ratio is standing at -15.82. The debt to equity ratio resting at -3.57. The interest coverage ratio of the stock is -46.16.
Currently, EBITDA for the company is -41.69 million with net debt to EBITDA at 0.09. When we switch over and look at the enterprise to sales, we see a ratio of 12.58. The receivables turnover for the company is 1.28for trailing twelve months and the total asset turnover is 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.72.
Conclusion
In conclusion, Vincerx Pharma Inc (VINC) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
